LAG3 and melanoma: The phase I study (NCT03005782) combining fianlimab (anti-LAG-3) and cemiplimab in advanced melanoma, including patients with previous neo/adjuvant treatment (phase III study combining fianlimab with cemiplimab in naïve metastatic melanoma pts-NCT05352672), shows promise in inducing durable responses [130].